Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- In trials, not approved
- ChEMBL max phase
- 3 / 4 (development scale, not regulatory approval)
- Synonyms
- Antithrombin; Antithrombine iii; Antithrombin iii; Antithrombin iii (human); Antithrombin iii human; Antithrombin iii, human; Antitrombina iii; Atenativ; At-iii; Atnativ; Heparin cofactor b; Kybernin; Kybernin p; ORG 10849; Thrombate iii
- Note
- Not recorded
Clinical trials 4
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Multicenter, Prospective, Open-label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
Congenital Antithrombin Deficiency
Enrolment: 38 · Results not recorded
Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery
Cardiopulmonary Bypass
Enrolment: 18 · Results not recorded
A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe Preeclampsia
Preeclampsia
Enrolment: 181 · Results not recorded
Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)
Preeclampsia
Enrolment: 120 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatIschaemia-reperfusionOther / unspecifiedWistarMalen = 60 male Wistar rats, 30 per group250 mg/kg30 minutes before reperfusion
Model: Lower-limb arterial occlusion for 6 hours followed by reperfusion, with remote lung and myocardial injury
Antithrombin III significantly lowered lung malondialdehyde at baseline and 30 minutes but not at 4 hours, indicating early protection against remote lung injury. No significant difference in myocardial malondialdehyde was found at any time point.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
